Advanced Proteome Therapeutics Corp.

Recent News

  • Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

    Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal, Bioconjugate Chemistry. Bioconjugate Chemistry is a peer-reviewed journal focused on bioconjugation and published by the American...

    2022-08-17 8:30 AM EDT
  • Advanced Proteome Therapeutics Receives Issued Patent

    Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled 'Composition and method for modifying polypeptides'. The patent covers highly site-selective antibody conjugate compositions produced with APTI's two-step conjugation technology including the half-product of the first...

    2022-08-03 1:45 PM EDT
  • Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

    Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.APTI has been informed that the first set of claims from US patent application 16/180,960 have been allowed. These claims cover highly site-selective antibody conjugate compositions produced with APTI's two step conjugation technology...

    2022-04-13 10:28 AM EDT
  • Advanced Proteome Therapeutics Announces Warrant Extension

    Vancouver, British Columbia--(Newsfile Corp. - March 18, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the "Warrants"). The Warrants' exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants issued to finders or...

    2022-03-18 3:46 PM EDT
  • Advanced Proteome Therapeutics Update on Plans for 2022

    Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is providing an update on plans for the upcoming year.APTI is pleased to report that, after operational advancements and continued antibody-drug conjugate (ADC) platform development and validation in 2021, 2022 is expected to be a transformational year. In July of 2021, Dr. Benjamin Krantz was appointed CEO of...

    2022-02-03 2:50 PM EST
  • Advanced Proteome Therapeutics Expands Operations

    Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is expanding operations with a new hire and additional lab space.APTI is pleased to report that it has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility. The expansion is part of APTI's plan to monetize its antibody-drug conjugate...

    2021-11-23 10:48 AM EST
  • Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's site-selective conjugation in the rapidly growing field of radioimmunoconjugates (RICs). The collaboration...

    2021-10-04 11:14 AM EDT
  • Advanced Proteome Therapeutics Provides Update on COVID Program

    Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and preliminary testing were initiated. In fall of last year, the program was deprioritized in the...

    2021-08-24 9:45 AM EDT